Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sunitinib malate works in treating younger patients with
recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.